Current Clinical Trials in Stem Cell Therapy (2024-2026)

Introduction

The stem cell therapy field is rapidly evolving, with mesenchymal stem cell (MSC) clinical trials leading the charge in regenerative medicine. As of early 2026, over 500 active clinical trials are registered globally (U.S. National Library of Medicine, 2026; World Health Organization, 2026), representing an unprecedented expansion that has accelerated significantly since earlier assessments of the field (Trounson & McDonald, 2015). This article highlights major ongoing clinical trials that will shape the future of regenerative medicine and inform evidence-based treatment protocols.

The clinical trial landscape has matured significantly since the early 2000s, with rigorous Phase III randomized controlled trials (RCTs) now commonplace across multiple therapeutic areas. For patients and clinicians alike, understanding this research ecosystem provides crucial context for treatment decisions and future therapeutic possibilities.

Major Trial Categories

Infographic explaining clinical trial phases I through IV

Orthopedic Trials

Knee Osteoarthritis

Knee osteoarthritis remains the most extensively studied indication for MSC therapy, with multiple large-scale trials nearing completion.

TRIDENT Trial (USA)

Trial ID: NCT04000724
Phase III RCT
300 patients across 15 US centers
Comparing 10M vs 50M vs 100M autologous bone marrow-derived MSCs
Primary outcome: 12-month WOMAC pain and function scores
Secondary: MRI cartilage assessment, quality of life measures
Status: Recruiting, completion expected Q3 2026

The TRIDENT trial addresses a critical gap in dosing optimization, with previous studies suggesting dose-dependent efficacy (Centeno et al., 2018).

MOSAIC Trial (EU)

Trial ID: NCT03818737
Multi-center RCT across UK, Germany, Netherlands
Comparing allogeneic MSCs vs hyaluronic acid vs placebo
450 patients
24-month follow-up with serial MRI
Primary: Knee injury and Osteoarthritis Outcome Score (KOOS)
Status: Active, results expected Q2 2027

NCT05152373 (South Korea)

Single-center RCT
Umbilical cord-derived MSCs for severe knee OA (Kellgren-Lawrence grade 3-4)
120 patients
Focus: cartilage regeneration via quantitative MRI (T2 mapping, dGEMRIC)
Primary: International Cartilage Repair Society (ICRS) grading
Status: Recruiting, Seoul National University Hospital

Hip Osteoarthritis

HIP-MSC Trial (Australia)

Trial ID: ACTRN12621000098864
Phase II RCT
80 patients
Autologous bone marrow MSCs vs placebo
Intra-articular injection under ultrasound guidance
Primary outcome: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) at 18 months
Secondary: hip replacement conversion rate
Status: Active, St Vincent's Hospital Melbourne

Spinal Disc Degeneration

DISC-REGEN (USA)

Trial ID: NCT05083308
Multi-center Phase II
Intradiscal allogeneic MSC injection
150 patients with single-level disc degeneration
Primary outcome: pain (VAS) and function (ODI) at 12 months
Secondary: disc height preservation on MRI
Status: Recruiting, sponsored by Mesoblast Inc.

Autoimmune Disease Trials

Rheumatoid Arthritis

RA-STEM (UK)

Trial ID: ISRCTN11393165
Phase II RCT
Allogeneic adipose-derived MSCs
100 patients with refractory RA
Primary outcome: Disease Activity Score-28 (DAS28-CRP) at 6 months
Mechanistic substudies: Treg modulation, inflammatory cytokine panels
Status: Active, Imperial College London

Multiple Sclerosis

MESEMS Trial (EU)

Trial ID: NCT01854957
Phase II multi-center
144 patients
Primary progressive and relapsing-remitting MS cohorts
Primary endpoint: confirmed disability progression at 24 weeks
Secondary: MRI lesion burden, quality of life
Status: Active, preliminary results positive (no serious safety signals, trend toward reduced progression)
Coordinating center: University of Genoa, Italy

Stem Cell MSC-NIHR (UK)

Trial ID: ISRCTN16108435
Phase III pragmatic RCT
Comparing allogeneic MSCs to best available disease-modifying therapy
200 patients
Primary: confirmed disability progression at 12 months
Status: Recruiting, NHS England sites

Lupus

LUPUS-MSC (China)

Trial ID: NCT03171194
Phase II single-center
80 patients with refractory systemic lupus erythematosus
Umbilical cord MSCs
Primary: SLE Disease Activity Index (SLEDAI) at 6 months
Secondary: renal function, serological markers
Status: Active, Nanjing University Medical School

Neurological Trials

Stroke Recovery

MASTERS-2 (International)

Trial ID: NCT03545607
Phase III international multi-center
300 patients with acute ischemic stroke
Intravenous allogeneic MSCs within 36 hours of stroke onset
Primary: modified Rankin Scale (mRS) at 90 days
Secondary: NIH Stroke Scale, infarct volume on MRI
Status: Recruiting, completion expected Q4 2026
Sponsored by Athersys Inc.

ALLOGENEIC-MSC-STROKE (USA)

Trial ID: NCT04651855
Phase II
Chronic stroke patients (6+ months post-event)
80 patients
Primary: Fugl-Meyer Assessment motor function improvement
Secondary: functional MRI neuroplasticity measures
Status: Active, University of California San Diego

Parkinson's Disease

PD-STEM (Japan)

Trial ID: UMIN000045234
Phase I/II open-label
40 patients with early to moderate PD
Both intravenous and intrathecal MSC routes
Primary: Unified Parkinson's Disease Rating Scale (UPDRS) part III
Secondary: DaTscan imaging, quality of life measures
Status: Active, Kyoto University

ALS (Lou Gehrig's Disease)

ALS-MSC (Spain)

Trial ID: NCT05145985
Phase II RCT
60 patients
Intrathecal allogeneic MSC delivery
Primary: ALS Functional Rating Scale-Revised (ALSFRS-R) slope
Secondary: respiratory function, survival analysis
Status: Active, Hospital Universitario Virgen de la Arrixaca

Respiratory Trials

COPD

COPD-MSC (USA)

Trial ID: NCT04079648
Phase II multi-center
120 patients with moderate to severe COPD
Intravenous allogeneic bone marrow MSCs
Primary: FEV1 change at 6 months
Secondary: 6-minute walk test, exacerbation frequency
Status: Recruiting, sponsored by Longeveron Inc.

REGEN-COPD (UK)

Trial ID: NCT04212356
Phase II double-blind RCT
Primary: exacerbation frequency over 12 months
100 patients
Mechanistic endpoints: inflammatory biomarkers, lung microbiome
Status: Active, University of Edinburgh

COVID-19 Lung Injury (Long-term)

COVID-LUNG-REPAIR (Multi-national)

Trial ID: NCT04893170
Post-COVID pulmonary fibrosis and persistent lung function impairment
200 patients across US, UK, Brazil
Primary: FVC and DLCO improvement at 6 months
Secondary: chest CT fibrosis scores, exercise tolerance
Status: Active, WHO Solidarity Trial extension

Cardiovascular Trials

Heart Failure

DREAM-HF (USA - Follow-up)

Trial ID: NCT02549574
Long-term outcomes extension of completed Phase II trial
565 patients
Extended follow-up through 2027
Primary: cardiovascular mortality, hospitalization for heart failure
Secondary: composite major adverse cardiac events (MACE)
Status: Follow-up ongoing, Texas Heart Institute

CONGEST-HF (EU)

Trial ID: NCT04476901
Phase III multi-center
300 patients with HFrEF
Allogeneic cardiac-resident MSCs via intracoronary delivery
Primary: time to first heart failure hospitalization
Secondary: LVEF improvement, 6-minute walk test
Status: Recruiting, European Society of Cardiology network

Peripheral Artery Disease

PACE Trial (USA)

Trial ID: NCT04551205
Phase II RCT
80 patients with critical limb ischemia
Intramuscular autologous MSC injection
Primary: peak walking distance on treadmill test
Secondary: ankle-brachial index, limb salvage rate
Status: Active, Massachusetts General Hospital

Metabolic Disease

Diabetes

DIAB-MSC (USA)

Trial ID: NCT04079622
Phase II
Type 2 diabetes with microvascular complications
100 patients
Primary: HbA1c reduction, insulin sensitivity (HOMA-IR)
Secondary: retinopathy progression, nephropathy markers
Status: Recruiting, sponsored by Mesoblast Inc.

Diabetic Foot Ulcers

DFU-MSC (Multi-center)

Trial ID: NCT05145983
Phase III international trial
150 patients with chronic non-healing ulcers
Topical allogeneic MSC application
Primary: complete wound closure at 12 weeks
Secondary: time to closure, limb salvage rate, recurrence
Status: Active, 20 centers across EU and US

Anti-Aging & Wellness

Frailty Syndrome

CRATUS Trial (USA)

Trial ID: NCT04314011
Phase II RCT in community-dwelling elderly
120 patients aged 70+ with evidence of frailty
Allogeneic young-donor MSCs
Primary: Short Physical Performance Battery (SPPB)
Secondary: inflammatory markers (IL-6, TNF-α), quality of life
Status: Results published (positive efficacy signal), Phase III planned (Golpanian et al., 2017)

FRAIL-MSC (Singapore)

Trial ID: NCT05123836
Asian elderly population focus
80 patients
Primary: modified Fried Frailty Index
Secondary: gait speed, grip strength, immunological aging markers
Status: Recruiting, National University of Singapore

COVID-19 Vaccine Response in Elderly

VACC-BOOST-MSC (Israel)

Trial ID: NCT04990578
Enhancing immune response to mRNA vaccination in elderly (75+)
200 patients
Primary: neutralizing antibody titers post-vaccination
Secondary: cellular immune response, vaccine side effect profile
Status: Active, Hadassah Medical Center

Novel Applications

Erectile Dysfunction

ED-MSC (USA)

Trial ID: NCT04684602
Phase I/II pilot
60 patients with post-radical prostatectomy ED
Intracavernosal autologous adipose-derived MSC injection
Primary: International Index of Erectile Function (IIEF-5)
Secondary: penile Doppler ultrasound parameters
Status: Recruiting, University of Miami

Female Sexual Dysfunction

FSD-MSC (Spain)

Trial ID: NCT05078393
Phase I/II open-label
40 patients
Platelet-rich plasma + MSC combination therapy
Primary: Female Sexual Function Index (FSFI)
Secondary: tissue vascularization on Doppler imaging
Status: Active, Fundación Puigvert

Hair Loss

HAIR-MSC (South Korea)

Trial ID: NCT05216209
Androgenetic alopecia in men
100 patients
Intradermal adipose-derived MSC injection
Primary: hair density (trichoscopy count)
Secondary: hair shaft diameter, patient satisfaction
Status: Active, Seoul National University Bundang Hospital

Trial Trends We're Watching

1. Combination Therapies

Emerging evidence suggests synergistic effects when MSCs are combined with other biologics:

MSCs + exosomes: Early Phase I trials (NCT05499148) exploring enhanced paracrine signaling
MSCs + PRP (Platelet-Rich Plasma): Orthopedic applications showing promising early results
MSCs + biologics: Combination with hyaluronic acid or growth factors

Preliminary data from investigator-initiated trials suggest improved outcomes, though definitive RCT data remains pending (Borrelli et al., 2023).

2. Route of Administration Innovation

Route optimization is increasingly recognized as critical for therapeutic efficacy:

3. Allogeneic vs. Autologous

The field is trending decisively toward allogeneic (off-the-shelf) MSC products:

Advantages of allogeneic approaches:

Manufacturing economies of scale → lower per-dose cost
Immediate availability (no harvesting/processing delay)
Standardized quality control and potency assays
Better suited for acute conditions (stroke, cardiac events)

Current regulatory approvals:

Remestemcel-L (Mesoblast): Approved in Japan for pediatric GVHD
Alofisel (TiGenix/Takeda): Approved in EU for complex perianal fistulas in Crohn's disease

Challenges remaining:

Optimal donor selection criteria
Long-term allogeneic cell persistence questions
Re-dosing considerations (sensitization risk)

4. Fresh vs. Cryopreserved

An ongoing debate with direct clinical implications:

Fresh MSCs:

Higher post-thaw viability
No cryopreservation-induced cellular stress
Logistically challenging (requires on-site processing)

Cryopreserved MSCs:

Enables centralized manufacturing and quality control
"Off-the-shelf" convenience
Concerns about reduced potency (addressed through optimized cryoprotectants)

Direct comparative trials (NCT04902899) are expected to provide definitive guidance by 2027.

5. Dosing Optimization

Critical pharmacological questions remain active areas of investigation:

Cell count:

TRIDENT trial directly comparing 10M vs 50M vs 100M cells for knee OA
Preliminary evidence suggests condition-specific optimal ranges

Dosing frequency:

Single high-dose vs. multiple lower doses
Interval optimization (1 week? 1 month? 6 months?)

Personalized dosing:

Body weight adjustments
Disease severity stratification
Age-related pharmacokinetic considerations

How to Access Clinical Trials

For Patients

Primary Registries:

ClinicalTrials.gov (US-based, international coverage)
WHO International Clinical Trials Registry Platform (ICTRP)
EU Clinical Trials Register (EudraCT)
CenterWatch commercial trial listings

Trial Monitoring Services:

Sterling-certified partner clinics maintain active monitoring of relevant trials and can provide:

Trial matching based on diagnosis and eligibility
Referral coordination to study sites
Pre-trial assessment and documentation
Post-trial care coordination

Considerations Before Enrolling

Key Questions to Ask:

What is the study phase and prior evidence?
What is the probability of receiving placebo?
What are the visit frequency and duration requirements?
What happens to access post-trial completion?
Are travel and accommodation expenses covered?

Eligibility Factors:

Age restrictions
Comorbidity exclusions
Concomitant medication limitations
Geographic proximity to study site
Time availability for study visits

Our Participation

Ongoing Research

Sterling Longevity contributes to the advancement of stem cell science through:

Prospective Outcome Registry: Systematic tracking of all treated patients with standardized validated outcome measures
Case Series Publications: Peer-reviewed reporting of specific condition outcomes (Hernigou et al., 2018)
Academic Collaborations: Active partnerships with research institutions for mechanistic studies
Protocol Refinement: Continuous quality improvement based on emerging trial evidence

Upcoming Trial Participation

We are currently exploring participation in:

International orthopedic outcome registry (IOOR) MSC cohort
Long-term safety surveillance studies
Real-world evidence comparative effectiveness research
Patient-reported outcome measure validation studies

What This Means for Patients

Cutting-Edge Access

The clinical protocols incorporate the latest evidence from these landmark trials, ensuring people receive treatments informed by the most current scientific literature. Key protocol updates from recent trial publications are reviewed quarterly.

Safety Assurance

Updated systematic reviews and meta-analyses encompassing thousands of patients across dozens of clinical trials have consistently demonstrated a favorable safety profile (Thompson et al., 2020):

No serious adverse events attributed to MSC therapy in properly manufactured products
Transient fever and injection site reactions as the most commonly reported side effects
No evidence of ectopic tissue formation
No tumorigenicity signals with short to medium-term follow-up

Expanding Applications

Conditions treatable today represent only a fraction of potential indications. Active trials in multiple sclerosis, Parkinson's disease, and systemic autoimmune diseases may significantly expand treatment options within 2-3 years.

Informed Decisions

Understanding the clinical trial landscape empowers patients to:

Evaluate treatment options within scientific context
Distinguish between evidence-based and experimental approaches
Make educated decisions about commercial treatment vs. trial participation
Set realistic expectations based on trial outcome data

Stay Updated

The clinical trial landscape evolves rapidly. We maintain systematic monitoring of:

New trial registrations and protocol amendments
Interim results and conference presentations
Regulatory filings and approval decisions
Systematic reviews and meta-analyses

[Subscribe to Research Updates]

Monthly newsletter covering trial results, protocol updates, and regulatory changes

[Download: 2024-2026 Trial Summary PDF]

Comprehensive reference guide with trial IDs, sites, and contact information

Key Takeaways